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Abstract 
Objective: To determine the impact of a proactive first day prescription counseling program on medication adherence to new 
cardiovascular maintenance medications 
Design:  Cross-sectional study 
Setting:  Regional chain community pharmacy in Pittsburgh, Pennsylvania; August 2009 through November 2010 
Patients: Data was collected from all patients aged 18-89 presenting with a new or transferred prescription or change in dosage 
within the study dates at four study locations 
Interventions: Patients presenting with a new or transferred prescription or change in dosage were identified to receive pharmacist 
or student pharmacist counseling. Data from the counseling session was tracked weekly to determine if the program increased 
adherence to statins, ACEIs and/or ARBs. 
Main Outcome Measured: Adherence to statins, ACEIs and/or ARBs was determined by differences in proportion of days covered 
(PDC) at six months and medication persistence to therapy. 
Results:  Analysis was conducted using IDNA
 sm
 software.  Results of the 6,916 prescriptions included in the study revealed that 
persistence rates for statins was 32.5% (intervention) and 34.2% (control) (p<0.001); ACEI/ARBs persistence was 37.3% (intervention) 
and 43.2% (control) (p<0.001).  PDC was nonsignificant with respect to statins; 43.2% (intervention) and 45.1% (control); and 50.2% 
(intervention) and 57.1% (control) (p<0.001) for the ACEI/ARBs. 
Conclusion: Results from this study showed no improvement in adherence of statins or ACEIs/ARBs with the D1TC program versus 
control pharmacies, although several important limitations were identified. It is clear that a variety of methods and programs are 
needed to consistently improve adherence to maintenance medications. 
 
Introduction  
Over 3.9 billion prescriptions are dispensed each year in the 
United States, primarily through retail pharmacies.
1,2
 
Pharmacist counseling is essential to optimize patient 
education and medication adherence and to prevent 
dangerous errors and adverse drug events. With the immense 
number of prescriptions dispensed through community 
pharmacy, pharmacists who work in this environment are in 
an optimal position to provide counseling to these patients. 
Pharmacist counseling is mandated by the US government via 
the Omnibus Reconciliation Act of 1990 (OBRA '90).  This law 
stipulates that all Medicaid patients receive the offer to  
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counsel when picking up a prescription. After the passing of 
this law, nearly all states responded by enacting and 
overseeing state-specific counseling regulations to all patients 
of the pharmacy, not just Medicaid patients.  However, one 
study found that, due to the nature in which the offer to 
counsel was presented, 69% of patients refused the offer to 
counsel and therefore did not receive in-person pharmacist 
counseling when filling their initial prescription.
3
 While OBRA 
'90 may appear antiquated with the advent of advanced 
pharmacist clinical counseling services such as mediation 
therapy management (MTM), it is still the reference point 
that requires that the offer to counsel be made. Many high-
volume community pharmacies are more apt to comply with 
this regulation due to the lack of time or resources required 
for MTM-based discussions. 
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Medication errors and poor medication adherence have been 
referred to as epidemics. Medication counseling and 
improved communication at retail pharmacies could help 
these issues.  Therefore, one particular regional chain 
pharmacy ("the pharmacy") with stores located in 
Pennsylvania, Ohio and Maryland, has piloted a clinical 
counseling program entitled Day 1 Therapy Counseling 
(D1TC). The purpose of this counseling program is for the 
pharmacist to take a proactive approach in counseling all 
patients receiving new prescriptions. In this manner, the 
patient is not asked whether they would like to receive 
counseling, since this could result in patients refusing the 
counseling service. Instead, in the D1TC program, all patients 
receiving new prescriptions are moved to a private counseling 
area to receive counseling by the pharmacist or student 
pharmacist. 
 
This program is currently being implemented in several store 
locations which have been identified as clinical sites. 
Implementation of this pilot program at certain stores has 
been aided with the help of a school of pharmacy faculty 
member and student pharmacists.   The universal objectives 
of the D1TC program have been stated by the pharmacy to 
"improve customer service, customer loyalty, and therapy 
management."  Within this program, customers beginning 
any new drug therapy (defined as a medication the patient 
has not received within the last six months or a transferred 
prescription from another pharmacy) or having a change in 
their medication dosage will be targeted to receive 
pharmacist or student pharmacist counseling on their 
prescription medication. Although all patients benefit from 
pharmacist counseling, this program is modeled to ensure 
that at the minimum, all patients receiving new prescription 
medications (as defined above) are identified to receive 
pharmacist or student pharmacist counseling, rather than the 
standard offer to counsel.  While the D1TC program was 
developed to provide counseling on all new prescriptions, this 
pilot study focused on adherence with select cardiovascular 
medications, specifically statins, ACEIs, and ARBs, after 
receiving counseling as a result of this program. Day 1 
Therapy interactions aim to educate the patient regarding the 
name of their medication, directions for use, indications, side 
effects, interactions, and any other unique properties of the 
therapy that may affect patient outcomes.  By ensuring 
proper use of the medication, patient medication adherence, 
and thus, health outcomes, can be optimized.   
 
Objective 
The primary objective of this study was to determine the 
impact of the Day 1 Therapy Counseling (D1TC) program on 
medication adherence to new medications (as defined by the 
D1TC program), specifically statins, ACEIs, and ARBs. 
Methods  
Study Design 
A prospective cross-sectional comparison of two locations of 
a regional chain grocery store pharmacy, with two similarly 
matched stores based on volume and demographics serving 
as control, were chosen to pilot the D1TC program in 
conjunction with a shared faculty member and experiential 
student pharmacists. Through this program, patients aged 18-
89 with all new prescriptions, transfers, or changes in dosage 
were flagged to receive counseling by the pharmacist or 
student pharmacist between 8/2009 and 11/2010. Data 
collected from the counseling session included time spent 
counseling, medication accuracy, patient satisfaction, as well 
as any additional comments. This information was input into 
a computer tracking system immediately following each 
counseling encounter.  The program was tracked weekly at 
the pharmacy corporate level to determine the percentage of 
prescriptions eligible for the program and those that actually 
received counseling services.  Adherence data for statins, 
ACEI/ARBs was accessed retrospectively in November 2010, 
after the initial pilot phase of the program.  The study was IRB 
approved, however patient consent was waived since 
pharmacist or student pharmacist counseling is a normal 
process of care. 
 
As this was a pilot program, after conclusion of the study a 
Survey Monkey® questionnaire was sent to all fourteen 
locations of the pharmacy that had a D1TC program in place, 
not just the two intervention stores, to assess the pharmacy 
staff's perceived barriers with implementation of this 
program. The two intervention stores included in this 
research project were part of the total 14 stores that have a 
D1TC program in place, whereas the control stores were not.  
Results of this survey are addressed in the discussion section. 
 
Site Selection 
Two of the pharmacy locations in Pittsburgh, Pennsylvania 
which have piloted the D1TC program were chosen for 
inclusion in this study as the intervention group.   These 
pharmacy locations were chosen for  several factors: access 
to a shared clinical faculty member from the participating 
school of pharmacy, fourth-professional year experiential 
student pharmacists rotating through the site year-round, 
and the length of time that these locations have been 
involved in the D1TC program (since August 2009).  The two 
pharmacy locations serving as the control group do not 
currently offer the D1TC program.  The control locations were 
selected due to similar prescription volume, staffing, 
geographic location, and patient and pharmacist 
characteristics as the intervention pharmacies.  Similar to the 
intervention stores, the control stores also have access to 
experiential student pharmacists.  The pharmacists in the 
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control stores provided patient counseling as required by 
OBRA regulations, but did not have the proactive D1TC 
program in place, nor was data on length of counseling time, 
patient satisfaction, or medication accuracy tracked.  Only 
prescription claims data were extracted to assess for 
medication adherence to the targeted medications. 
 
Survey Instrument 
Figure 1 illustrates the form used to collect data from the 
D1TC program counseling sessions. This form, which is 
stapled to all prescription bags containing medications that fit 
the criteria of the D1TC program, is a full-length sheet of 
paper that includes all pertinent information needed for the 
pharmacist or student pharmacist to conduct a counseling 
session with the patient when they return to pick up their 
prescription.  The top of the paper indicates that the 
prescription is a D1TC program prescription. Below, 
prescription demographical information such as patient 
name, date of birth, and prescription number are listed.  A 
separate box under the prescription identifiers contains the 
name of the new prescription (medication name, dose, and 
dosage form), directions for use, and prescriber name.  This 
information is contained within a box to differentiate it from 
other information on the paper.  At the bottom of the D1TC 
program sheet, the patient's active pharmacy profile 
information within the last 12 months is listed. This is 
pertinent to the success of incorporating the D1TC program 
into pharmacy workflow. By having access to all of the 
patient's current medications, the pharmacist or student 
pharmacist providing the counseling will not have to return to 
a computer to look up this information. The information 
included in this active profile section includes medication 
name, dose, dosage form, prescription number, first and last 
fill dates, quantity dispensed, and prescribing physician.  
Since this form only includes active profile information for the 
pharmacy filling the prescription, pharmacists and student 
pharmacists were trained to ask the patient about 
medications filled from other pharmacies as well as over-the-
counter and herbal medications they might be taking, for 
purposes of a comprehensive and accurate counseling 
session.   The last component of the D1TC program paper is a 
documentation box that is to be filled out by the person 
performing the counseling session. This documents the date 
of counseling, start and stop time of the counseling session 
(to quantify the number of minutes spent counseling), and 
the initials of the person providing the counseling.  The 
person documenting the counseling session is also asked to 
indicate whether the correct medication was dispensed, if 
patient contact was made and whether it was a positive or 
negative encounter, and to add any additional comments that 
should be documented.  While caregivers or spouses picking 
up a prescription could not be controlled for, the positive or 
negative patient experience was still documented for quality 
improvement measures. 
 
Workflow 
The standard process by which the D1TC program occurs 
during everyday workflow is as follows. During the NDC 
verification, or final check phase of dispensing, the computer 
system will indicate that the prescription meets criteria 
described above for inclusion into the D1TC program. The 
pharmacist at that station will then click the screen to print 
the D1TC program form which was described above. This 
form is stapled to the bag, which is then placed into the pick-
up drawer until the patient returns for their prescription. 
 When the patient returns to pick up their prescription, the 
cashier or technician will see the paper on the top of the bag 
indicating that this is a new prescription requiring counseling. 
All pharmacy staff has been trained in the proper dialogue to 
use with patients picking up prescriptions within this 
program. Rather than extending the offer to counsel (as 
required by OBRA '90), patients are told that the pharmacist 
wishes to speak to them, and asked to step to the 
consultation window. The pharmacist or student pharmacist 
then takes the D1TC program paper and provides counseling 
to the patient on their prescription. After the counseling 
session has concluded, the pharmacist or student pharmacist 
completes the documentation section of the paper. Data 
from these papers are then entered into the computer 
system to track the percentage of counseling opportunities 
that occurred and were acted upon. 
 
 Staffing and Hours 
The current pilot of the D1TC program does not incorporate 
any additional pharmacist or student pharmacist staffing 
hours and occurs at designated stores during normal 
pharmacy operating hours.  Currently, a non-staffing school 
of pharmacy faculty member and fourth-year experiential 
student pharmacists have aided in the implementation of this 
program at the intervention stores included in this study. The 
faculty member held a standardized training for each group 
of experiential student pharmacists prior to their rotation at 
the pharmacy locations. This training included an overview of 
the D1TC program, directions on how to input the data for 
tracking purposes, and a review of counseling points for the 
selected medication classes (statins, ACEIs, and ARBs).  The 
staffing pharmacists at the stores were trained in the same 
way as the student pharmacists prior to implementation of 
the D1TC program.  The faculty member rotated between the 
two intervention sites to aid in implementation of the D1TC 
program into the pharmacy daily workflow system.  Due to 
the faculty member having academic obligations at the 
university as well as two pharmacy location sites, not every 
patient encounter was monitored; however, during time 
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spent at the stores, the faculty member oversaw student 
counseling sessions to ensure accuracy of information 
conveyed and that each completed interaction was properly 
documented.  The faculty member also acted as a non-
dispensing pharmacist to help ensure that an attempt was 
made to counsel on all new prescriptions during high-volume 
times in the pharmacy.   
 
Analysis   
Patients were included in the study analysis if they initiated a 
retail prescription for a statin, ACEI or ARB medication at any 
of the study locations between August 1, 2009 and November 
30, 2010.  These medications were selected based on their 
high prescription volume in these pharmacy locations.  
Following IRB approval, prescription claims for the identified 
medications were then extracted into a database for the 
period and were then uploaded to IDNA
sm
, a web-based data 
analytic platform to create customized medication adherence 
analyses and reports using medical and pharmacy utilization 
data.  Primary endpoints included differences in adherence 
metrics between the D1TC stores and controls, including 
proportion of days covered (PDC) at 6 months and 
medication persistence to therapy as measured by IDNA
sm
.  
PDC was calculated by taking the patient’s total days supplied 
of the medication classes for the 180 day period following the 
index date of fill and dividing by 180.  This method permitted 
adherence based on the entire 6 months and not on patients’ 
persistence periods.  Persistence was calculated as the 
number of days between the patient’s index prescription until 
the end of 6 months or the date of discontinuation, 
whichever came first, with the application of a 15-day refill 
grace period.  Medication persistence was evaluated at a 
class level; patients who switched medications within their 
index medication class but did not exceed a permissible gap 
were considered persistent.  Descriptive statistics were used 
for demographical variables and chi square tests to compare 
D1TC stores with controls for persistence rates and PDC.  Also 
noted in the discussion section of this report is a concurrent 
assessment of pharmacist's perceived barriers to 
implementation of the Day 1 Therapy Counseling program. 
 
Results 
There were over 78,434 patients with a prescription that met 
the Day 1 Therapy Counseling program criteria (a new 
prescription, transfer, or change in dosage). This total 
number included all prescriptions dispensed at the Day 1 
pharmacies that met the D1TC program criteria and was not 
limited to the medication classes of statins, ACEI/ARBs.  Of 
those 78,434 patients with a prescription meeting the 
program criteria, 40,671 (51.9%) received brief counseling by 
a pharmacist or student pharmacist on their prescription 
(average counseling time <2 minutes).  This resulted in a 
counseling rate of 45.2 prescriptions per day per location.  
While 40,671 patients received counseling on their Day 1 
prescription, only 6,916 of those prescriptions were for a 
statin, ACEI/ARB, and therefore were included in the study 
analysis.   With concurrent utilization of medications from 
both classes, the therapy cohorts were 3,948 ACEI/ARB 
patients and 3,555 statin patients; mean age was 61.5 (18-
89).  The percentage of males was 54.3% (n=3752). (see table 
1: baseline characteristics)  
At 6 months post-index, persistence rates for statins for the 
D1TC stores were 32.5% and controls 34.2% (p<0.001), 
respectively.  The persistence rates for ACEI/ARBs for the 
D1TC stores were 37.3% and controls were 43.2% (p<0.001), 
respectively. The PDC for statins at D1TC stores was 43.2% 
and control was 45.1%. (p=NS).   The PDC for ACEI/ARBs at 
D1TC stores was 50.2% and control was 57.1% (p<0.001). (see 
table 2: persistence and PDC) 
 
Discussion  
This study sought to investigate the impact of a piloted 
proactive counseling program on patient adherence to the 
medication classes of statins and ACEI/ARBs.  Previous 
internal surveys of this program revealed high patient 
satisfaction with this counseling approach; however, this was 
the first attempt to measure the impact on medication 
adherence with the initiation of a Day 1 Therapy Counseling 
program.  Results from this study demonstrated better 
adherence rates, as measured by PDC and medication 
persistence, for the control stores versus those that had the 
D1TC intervention. While this result appears to contradict 
what current literature supports, there are several important 
factors that must be considered.  First and foremost, the 
D1TC program revealed that there was only a brief amount of 
time spent in the counseling session (<2 minutes).  Many 
studies have shown counseling interventions that successfully 
improve adherence generally involve a greater amount of 
time.  McDonald et al. conducted a systematic review that 
showed most studies do not specify an optimal amount of 
counseling time that is required to see increases in 
medication adherence; however, they do point out that one 
study showed a minimum of a 20 minute initial consultation 
was needed to see an increase in short-term patient 
compliance with their medication regimen.
4
 Other studies 
showed that a more involved pharmacist intervention to 
simplify the patient's medication dosing regimen resulted in 
greater adherence for patients with chronic conditions such 
as hypercholesterolemia or hypertension.
4 
 Lastly, many 
studies support the counseling technique of motivational 
interviewing to improve patient adherence. In this patient-
centered approach, the pharmacist attempts to enhance the 
patient's own intrinsic motivation to change by exploring and 
resolving ambivalence.
5-6   
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While standard counseling points were reviewed with 
pharmacists and pharmacy students involved in the study, 
the brief counseling time did not allow for the 
aforementioned techniques to be employed.  Also, although 
all pharmacy employees were trained on the proper dialogue 
for engaging patients to participate in the counseling session 
with the pharmacist, it was often noted that during peak 
times in the pharmacy, staff would resort to the OBRA-
required method of asking the patient if they had questions 
for the pharmacist. When this occurred, the patient could 
more easily refuse pharmacist counseling.  If the patient 
denied pharmacist counseling, their adherence data was still 
analyzed in the intervention cohort with that of patients who 
actually received D1TC counseling.  In addition, the relatively 
lower number of prescriptions in the Day 1 Therapy group 
may have reduced statistical power to detect a change 
among the groups where no difference was observed.  It is 
the belief that, in accordance with other adherence studies, 
should the patients in the intervention group be engaged in 
the counseling session for a longer period of time, a more 
positive impact on adherence would result. 
At the completion of data analysis, a survey was sent to all 
pharmacies participating in the D1TC program, not just the 
study locations, to assess perceived barriers to 
implementation of the counseling program into daily 
workflow.  A total number of 175 pharmacy staff, including 
pharmacists, technicians and student pharmacists/interns, 
was eligible to take the survey which was distributed via 
email. The survey was created using Survey Monkey
®  
which 
allowed for anonymous collection of participant responses.  A 
total of 38 responses were collected from the survey, 
resulting in a 21.7% response rate.  Of those respondents, 28 
identified themselves as pharmacists (73.7%), 4 were 
technicians (10.5%), and 6 were student pharmacists/interns 
(15.8%).  The top barriers identified in the survey by all 
respondents included lack of time to counsel (50.7%), 
patients appearing uninterested in receiving counseling 
(41.6%), and inadequate staffing (41%).   
 
Limitations 
One potential limitation in this study was the relatively lower 
number of prescriptions in the intervention group as 
compared to control. The intervention store analysis included 
the 6,916 new prescriptions for statins, ACEI/ARBs that 
received counseling, whereas the control store analysis 
included all new prescriptions for statins, ACEIs, and ARBs 
filled within the study dates where either the offer to counsel 
or pharmacist counseling took place.  It is also possible that 
other classes of medications, rather than the targeted 
medications, could have, by chance, had more consistent 
counseling. It is important to consider that the counseling of 
prescriptions through the D1TC program included all new 
prescriptions and was not limited to statins, ACEIs, or ARBs, 
although these were the medications selected for the 
purpose of this adherence study.  Several other limitations 
existed in this study which could have affected the results 
such as the majority of counseling that occurred was 
performed by fourth-professional year student pharmacists 
(>89%). While all pharmacists and student pharmacists were 
trained in a standard and reproducible manner, specific and 
uniform counseling points were not consistently used.  While 
most student pharmacists had acquired some community 
pharmacy experience by this point in their education, not all 
students had. Their medication knowledge was appropriate 
for a near-graduate of pharmacy school, however, for some, 
the art of counseling was still being learned.  Additionally, the 
short duration that the student pharmacists spent at the 
pharmacy while on rotation (5 weeks) prevented them from 
developing the same rapport with the patient as the 
pharmacists who consistently worked there.  Although it is 
unlikely that the students had a causal effect on reducing 
adherence rates, these potential limitations must be 
considered.  
  
Conclusion 
The results of this study show that the proactive D1TC 
program did not improve adherence rates as compared to 
control locations that did not have the program in place.  
Based on the findings of this pilot study, community 
pharmacists can work to improve medication adherence by 
tailoring the counseling session to the patient and addressing 
patient-related issues such as affordability, fear of adverse 
effects, motivation for change, and understanding of 
disease/medication. While this particular regional pharmacy 
has taken initial steps with the development of the D1TC 
program, improvements to this program may help to improve 
adherence rates.  Future plans include re-assessment of the 
D1TC program on adherence rates utilizing additional 
pharmacist resources such as additional counseling time.  
Also, adherence data between patients in the D1TC program 
and those undergoing a full medication therapy management 
session will be compared. 
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Figure 1. Day 1 Therapy Counseling Data Collection Form 
 
 
 
Figure 2. Patients Participating in D1TC program 
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             1591 – Day 1      1451- Day 1 
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Figure 3.  Six Month Persistence 
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Table 1. Baseline Characteristics 
Characteristic Statins  
(N=3555) 
ACEI/ARBs 
(N=3948) 
Age 
Mean ±SD (min, max) 62.8 ±12.8 (18, 89) 61.8± 15.1 (18,89) 
Gender 
N(%) 
Male  
 
1977 (55.6%) 2159 (54.7%) 
 
 
Table 2. Persistence and PDC 
 Intervention Stores Control Stores 
Statin 
Persistence 
                                 PDC 
 
 
32.5% (p < 0.001) 
43.2% (NS) 
 
34.2%  
45.1%  
ACEI/ ARBs 
Persistence 
                                 PDC 
 
 
37.3% (p < 0.001) 
50.2% (p < 0.001) 
 
 
43.2% 
57.1% 
 
 
